| Autor: |
Beach, Judith E., Goolsby, William A. |
| Zdroj: |
The Quality Assurance Journal; March 2003, Vol. 7 Issue: 1 p22-31, 10p |
| Abstrakt: |
From the trend in modern medicine toward the study of genes and their contribution to the development of disease has evolved an increased awareness of ‘the diversity of genetic fingerprints among individuals’ [1]. The incorporation of this knowledge into the technologies of the pharmaceutical industry has led to the emerging field of ‘pharmacogenomics’; that is, the process of identifying the differences in genetic sequences between individuals and developing therapies [2] as ‘personal medicines’ [3]. For example, a drug used as a muscle relaxant during surgery, suxamethonium, was found to be lethal to patients who possessed a rare version of a gene involved in nerve transmission so that now those who receive this drug are tested for this specific gene [4]. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text